Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tenofovir Exalidex Oral Formulations in Healthy Subjects
NCT03279146Phase 1Completed
- Sponsor
- Hepion Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir exalidex in hepatitis B (HBV) (3 arms), sponsored by Hepion Pharmaceuticals. Primary endpoint: Pharmacokinetics of single dose oral formulations of TXL. Started Sep 2017; status: completed.
02
Drugs
tenofovir exalidex
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03279146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279146.